PSMA-Val-Cit-PAB-MMAE
Based on 1 Customer Validation
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 2748039-79-2
- Formula: C114H165ClN20O26
- Molecular Weight:2267.10
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Auristatin |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CWR22R | CC50 |
29 nM
Compound: PSMA-Val-Cit-PAB-MMAE
|
Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay
|
[PMID: 34797052] |
| PC-3 | CC50 |
27 nM
Compound: PSMA-Val-Cit-PAB-MMAE
|
Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay
|
[PMID: 34797052] |
PSMA-Val-Cit-PAB-MMAE exhibits nanomolar cytotoxicity in both PSMA-expressing 22Rv1 and PSMA-null PC-3 human prostate cancer cell lines, with CC50 values of 29 nM and 27 nM, respectively[1].
PSMA-Val-Cit-PAB-MMAE (27-29 nM; 1 h) induces significant oxidative stress in 22Rv1 and PC-3 human prostate cancer cells, increasing intracellular hydrogen peroxide levels to twice and three times the control levels, respectively, after 1 h incubation at its CC50 concentration[1].
PSMA-Val-Cit-PAB-MMAE (27-29 nM; up to 40 min) significantly reduces the stiffness of 22Rv1 human prostate cancer cells after incubation at its CC50 concentration, but does not alter the stiffness of PC-3 human prostate cancer cells over 40 minutes[1].
PSMA-Val-Cit-PAB-MMAE (40 μM; up to 8 h) is efficiently cleaved by recombinant cathepsin B in a pH-dependent manner, with the fastest hydrolysis at pH 3.6, but the highest release of free MMAE occurs at pH 5.6[1].
PSMA-Val-Cit-PAB-MMAE (1-10000 μg/mL) does not induce gene mutations in Salmonella typhimurium strains TA98, TA97, or TA100 at concentrations up to 10000 μg/mL, with or without metabolic activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PSMA-Val-Cit-PAB-MMAE (0.3 mg/kg; i.v.; three times at five-day intervals) shows weak antitumor activity against low-PSMA PC-3 prostate cancer xenografts in nude mice, achieving a maximum 37.7% tumor growth inhibition[1].
PSMA-Val-Cit-PAB-MMAE (0.3 mg/kg; i.p.; daily; 5 days) exhibits potent antitumor activity against PSMA-positive 22Rv1 prostate cancer xenografts in nude mice, achieving 70−85% tumor growth inhibition with 100% survival[1].
PSMA-Val-Cit-PAB-MMAE (0.2-0.4 mg/kg; i.p.; daily; 5 days) inhibits tumor growth in DU145 prostate cancer xenografts in nude mice[1].
PSMA-Val-Cit-PAB-MMAE (2-60 mg/kg; i.v.; single dose) has a median lethal dose of 6.3 mg/kg in healthy male ICR mice following a single intravenous injection, resulting in a therapeutic index of 21[1].
PSMA-Val-Cit-PAB-MMAE (1-30 mg/kg; i.v.; single dose) has a median lethal dose of 4.9 mg/kg in healthy male Wistar rats following a single intravenous injection[1].
PSMA-Val-Cit-PAB-MMAE (150-225 μg/kg; i.v.; once every three weeks; three months) exhibits moderate chronic toxicity in healthy male Wistar rats, with dose-dependent testicular pathology and transient gastrointestinal effects at the highest tested dose of 225 μg/kg, and no mortality observed[1].
PSMA-Val-Cit-PAB-MMAE (81-122 μg/kg; i.v.; once every three weeks; three months) exhibits moderate chronic toxicity in healthy male Soviet Chinchilla rabbits, with one death in the highest dose group, immunological and pancreatic effects, and testicular pathology observed in some animals[1].
PSMA-Val-Cit-PAB-MMAE (up to 14 mg/kg cumulative; i.v.; daily) does not exhibit significant cumulative toxicity in healthy male Wistar rats with daily repeated intravenous injections, as indicated by a cumulation index of 1.45, despite increased mortality with higher cumulative doses[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu (male, 8−10 weeks old, 21−25 g, subcutaneous xenograft of 22Rv1 PSMA-positive human prostate carcinoma cells)[1]
-
Dosage:0.3 mg/kg
-
Administration:i.v.; three times at five-day intervals
-
Result:Achieved tumor growth inhibition (TGI) ranging from 77.4−84.5% relative to the control group.
Had no effect on the general condition or body weight of the mice.
-
Animal Model:BALB/c nu/nu (male, 8−10 weeks old, 21−25 g, subcutaneous xenograft of PC-3 low-PSMA human prostate adenocarcinoma cells)[1]
-
Dosage:0.3 mg/kg
-
Administration:i.v.; three times at five-day intervals
-
Result:Achieved tumor growth inhibition (TGI) not exceeding 37.7% relative to the control group.
Had no effect on the general condition or body weight of the mice.
-
Animal Model:Nude mice (male, subcutaneous xenograft of 22Rv1 PSMA-positive human prostate carcinoma cells)[1]
-
Dosage:0.3 mg/kg
-
Administration:i.p.; daily; 5 days
-
Result:Maintained 100% mice survival during the experiment.
Achieved tumor growth inhibition (TGI) ranging from 70−85% relative to the control group.
-
Animal Model:Nude mice (male, subcutaneous xenograft of DU145 human prostate cancer cells)[1]
-
Dosage:0.2 mg/kg; 0.4 mg/kg
-
Administration:i.p.; daily; 5 days
-
Result:Reduced average tumor volume relative to the control group at both 0.2 mg/kg and 0.4 mg/kg.
Inhibited tumor growth to levels comparable to low-dose docetaxel groups.
-
Animal Model:ICR (male, ~2 months old, 19−21 g)[1]
-
Dosage:2 mg/kg; 3 mg/kg; 5 mg/kg; 6 mg/kg; 7 mg/kg; 8 mg/kg; 9 mg/kg; 30 mg/kg; 45 mg/kg; 60 mg/kg
-
Administration:i.v.; single dose
-
Result:Resulted in a median lethal dose (LD50) of 6.3 mg/kg.
Produced a therapeutic index of 21, calculated as LD50/ED50.
-
Animal Model:Wistar (male, ~2 months old, 190−210 g)[1]
-
Dosage:1 mg/kg; 2 mg/kg; 3 mg/kg; 4 mg/kg; 4.5 mg/kg; 5 mg/kg; 5.1 mg/kg; 5.4 mg/kg; 6 mg/kg; 8 mg/kg; 9 mg/kg; 15 mg/kg; 23 mg/kg; 30 mg/kg
-
Administration:i.v.; single dose
-
Result:Resulted in a median lethal dose (LD50) of 4.9 mg/kg.
-
Animal Model:Wistar (male, ~2 months old, 190−210 g)[1]
-
Dosage:150 μg/kg; 188 μg/kg; 225 μg/kg
-
Administration:i.v.; once every three weeks; three months
-
Result:Ensured all rats survived to the end of the experiment.
Caused externally visible signs of intoxication (diarrhea resolving within seven days post-injection) only in the 225 μg/kg group.
Induced dose-dependent hypo- and aplasia of spermatogenesis in the testes.
Resulted in body weight changes significantly different from controls only at the highest dose, with changes not constant.
-
Animal Model:Soviet Chinchilla (male, ~2 months old, 2.0−2.2 kg)[1]
-
Dosage:81 μg/kg; 102 μg/kg; 122 μg/kg
-
Administration:i.v.; once every three weeks; three months
-
Result:Caused one death in the 122 μg/kg group after the second injection; all other rabbits survived.
Induced decreased blood lymphocyte counts and increased glucose levels.
Caused hypo- and aplasia of spermatogenesis in some animals, with no clear dose-dependence.
Resulted in body weight changes significantly different from controls only at the highest dose, with changes not constant.
Chemical Information
-
CAS No. 2748039-79-2
-
Appearance Solid
-
Molecular Weight 2267.10
-
Formula C114H165ClN20O26
-
Color White to off-white
-
SMILES
OC(CC[C@@H](C(O)=O)NC(N[C@@H](CCCCN(CC1=CC(Cl)=CC=C1)C(CCCCCNC(CCC(N[C@H](C(N[C@H](C(NCCCN2N=NC(CCCC(N[C@H](C(N[C@H](C(NC3=CC=C(C=C3)COC(N([C@H](C(N[C@@H](C(C)C)C(N([C@H]([C@@H](CC(N4CCC[C@]4([C@@H]([C@@H](C)C(N[C@@H]([C@H](C5=CC=CC=C5)O)C)=O)OC)[H])=O)OC)[C@@H](C)CC)C)=O)=O)C(C)C)C)=O)=O)CCCNC(N)=O)=O)C(C)C)=O)=C2)=O)CC6=CC=C(C=C6)O)=O)CC7=CC=CC=C7)=O)=O)=O)C(O)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (44.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (293 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4411 mL | 2.2055 mL | 4.4109 mL | 11.0273 mL |
| 5 mM | 0.0882 mL | 0.4411 mL | 0.8822 mL | 2.2055 mL | |
| 10 mM | 0.0441 mL | 0.2205 mL | 0.4411 mL | 1.1027 mL | |
| 15 mM | 0.0294 mL | 0.1470 mL | 0.2941 mL | 0.7352 mL | |
| 20 mM | 0.0221 mL | 0.1103 mL | 0.2205 mL | 0.5514 mL | |
| 25 mM | 0.0176 mL | 0.0882 mL | 0.1764 mL | 0.4411 mL | |
| 30 mM | 0.0147 mL | 0.0735 mL | 0.1470 mL | 0.3676 mL | |
| 40 mM | 0.0110 mL | 0.0551 mL | 0.1103 mL | 0.2757 mL |
PSMA-Val-Cit-PAB-MMAE Related Classifications
HY-141860 Related Classifications
Powered by Bioz